ATE500848T1 - Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein - Google Patents

Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein

Info

Publication number
ATE500848T1
ATE500848T1 AT06818201T AT06818201T ATE500848T1 AT E500848 T1 ATE500848 T1 AT E500848T1 AT 06818201 T AT06818201 T AT 06818201T AT 06818201 T AT06818201 T AT 06818201T AT E500848 T1 ATE500848 T1 AT E500848T1
Authority
AT
Austria
Prior art keywords
heterocomplexes
carrier protein
aplha
tnf
antigen
Prior art date
Application number
AT06818201T
Other languages
English (en)
Inventor
Daniel Zagury
Buanec Helene Le
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs filed Critical Neovacs
Application granted granted Critical
Publication of ATE500848T1 publication Critical patent/ATE500848T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT06818201T 2005-05-24 2006-05-24 Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein ATE500848T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05300404 2005-05-24
PCT/EP2006/005044 WO2007022813A2 (en) 2005-05-24 2006-05-24 A METHOD FOR PREPARING A STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES OF TNFα AND A CARRIER PROTEIN

Publications (1)

Publication Number Publication Date
ATE500848T1 true ATE500848T1 (de) 2011-03-15

Family

ID=35746986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06818201T ATE500848T1 (de) 2005-05-24 2006-05-24 Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein

Country Status (13)

Country Link
US (1) US7887811B2 (de)
EP (1) EP1888122B1 (de)
JP (1) JP5061099B2 (de)
CN (1) CN101222941A (de)
AT (1) ATE500848T1 (de)
AU (1) AU2006284248B2 (de)
BR (1) BRPI0609932A2 (de)
CA (1) CA2609572C (de)
DE (1) DE602006020563D1 (de)
ES (1) ES2382229T3 (de)
NZ (1) NZ563526A (de)
WO (1) WO2007022813A2 (de)
ZA (1) ZA200710011B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2725035A1 (de) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antikörpertherapie zur Verwendung im Verdauungstrakt
RU2581020C2 (ru) * 2009-12-22 2016-04-10 Селлдекс Терапьютикс, Инк. Композиции вакцин
EP2462950A1 (de) 2010-12-08 2012-06-13 Neovacs Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung
MX2013006501A (es) 2010-12-08 2014-02-28 Neovacs Vacuna fuertemente inactivada y todavia sumamente inmunogenica, y proceso para su fabricacion.
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
AU2012290104A1 (en) * 2011-08-01 2014-02-13 Avaxia Biologics, Inc. Bovine polyclonal antibody specific for human TNF
WO2015017683A1 (en) * 2013-07-31 2015-02-05 Malast Mary Antimicrobial compositions and methods of use
US9733162B2 (en) 2014-02-11 2017-08-15 Ihor Turkevych Universal system, method and solution for the acceleration of the process of fixing, dehydrating and clearing the structure of biological tissue
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
CN115594770B (zh) * 2022-12-14 2023-04-07 上海惠盾因泰生物科技有限公司 一种针对人TNFα分子的类风湿关节炎治疗性疫苗的构建

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5578308A (en) * 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
FR2812813B1 (fr) * 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
ITMI20010571A1 (it) 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation

Also Published As

Publication number Publication date
NZ563526A (en) 2009-02-28
JP2008542227A (ja) 2008-11-27
ZA200710011B (en) 2008-10-29
DE602006020563D1 (de) 2011-04-21
US7887811B2 (en) 2011-02-15
CN101222941A (zh) 2008-07-16
JP5061099B2 (ja) 2012-10-31
US20080193473A1 (en) 2008-08-14
WO2007022813A3 (en) 2007-04-26
ES2382229T3 (es) 2012-06-06
CA2609572A1 (en) 2007-03-01
EP1888122B1 (de) 2011-03-09
CA2609572C (en) 2013-11-19
BRPI0609932A2 (pt) 2011-10-11
AU2006284248B2 (en) 2010-10-07
AU2006284248A1 (en) 2007-03-01
EP1888122A2 (de) 2008-02-20
WO2007022813A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
ATE500848T1 (de) Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
ATE444950T1 (de) Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
ATE533019T1 (de) Verfahren zur herstellung eines pulverförmigen produkts
WO2009010877A3 (en) Conjugate purification
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
ATE360653T1 (de) Verfahren zur herstellung von polyisobutenen
ATE486841T1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
ATE542518T1 (de) Verfahren zur herstellung eines zweifarbigen kosmetikums
ATE430559T1 (de) Verfahren zur herstellung von calciumzusammensetzungen im kontinuierlichen fliessbett
ATE376997T1 (de) Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
DE602006013151D1 (de) Verfahren zur herstellung von polymermaleimiden
ATE528026T1 (de) Verfahren zur herstellung eines künstlichen gelenks
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten
DE602005021380D1 (de) Verfahren zur herstellung eines luftreifens
DE602004030603D1 (de) Verfahren zur herstellung gamma-carboxylierter proteine
DE60205676D1 (de) Verfahren zur Herstellung eines Gegenstandes
WO2006106424A3 (en) Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
ATE374755T1 (de) Verfahren zur herstellung von 1,3,5- triazincarbamaten und -harnstoffen
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t
DE602005016377D1 (de) Geformter holzartikel und verfahren zur herstellung des geformten holzartikels
ATE537187T1 (de) Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendung
DE602005026841D1 (de) Verfahren zur herstellung von 1,2,2,2-tetrafluor-ethyl-difluor-methylether
ATE418642T1 (de) Verfahren zur herstellung eines einbügelbaren einlagestoffs, sowie dadurch hergestellter einlagestoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties